The creative services division of Ross Video, Rocket Surgery, and Arcturus have signed an agreement aimed at promoting ...

The two brightest nighttime stars available in the Shamokin sky are Sirius and Arcturus. April is the only month of the year ...

The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.

Arcturus Therapeutics (ARCT) announced that the FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company ...

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $71 and keeps a Buy rating on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect ( DRRX – Research Report) today. The company’s shares opened today at $0.81.

TriSpan, the investment company behind the three brands, has announced plans to bring the brands together under new holding group Arcturus Group, as part of its Rising Stars fund, which invests in ...

The drug, a once-daily pill called Vykat XR, was developed by Soleno Therapeutics. “The approval of Vykat XR is a significant milestone for Soleno and, most importantly, for the PWS community ...